Our Biotechnology IP group comprises a team of more than 20 attorneys and patent agents, the majority of whom have M.Sc. or Ph.D. graduate degrees, and includes experienced scientists and skilled engineers. Their extensive knowledge of Life Science disciplines provides a deep understanding of our clients’ needs in this arena. Notably, Honigman was awarded the “U.S. – Firm to Watch” in 2020 as well as the “Patent Prosecution Firm of the Year” in 2021 for the Midwest by Managing Intellectual Property.
We have a broad range of experience with global pharmaceutical and biotechnology IP related procedures, patent filings, and regulatory requirements. Clients benefit from our demonstrated knowledge of pharmaceutical, biotechnology, medical device global patent post-grant proceedings and litigation. We have developed and implemented global IP patent procurement strategies for FDA approved biologics and medical devices, and diagnostics including IP strategic planning, studies on patentability, infringement and validity, IP audits and due diligence, licensing and technology transfer.
Our patent attorneys routinely assist clients with freedom to operate and competitor analyses for a wide range of pharmaceutical and biotechnology candidate therapies. In addition, because our team is highly integrated with the firm’s corporate, litigation, and transactional practices, we provide value by efficiently delivering services while containing costs. We strive to exceed our client’s expectations in service delivery standards, communication, and consistent results.
Connect with a Professional
2021 Patent Prosecution
Firm of the Year
Managing Intellectual Property
2020 Firm to Watch